MyoPax receives B# Plus financing from IBB Ventures as the first startup under the program — developing gene repair therapy for genetic muscular dystrophy.
MyoPax is dedicated to delivering effective muscle regeneration therapies that restore muscle function, utilizing advanced stem cell manufacturing, cell engineering, and gene-editing technologies
MyoPax is dedicated to delivering effective muscle regeneration therapies that restore muscle function, utilizing advanced stem cell manufacturing, cell engineering, and gene-editing technologies.